Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems

Phase 2 Completed 78 enrolled Supernus Pharmaceuticals, Inc.

RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective was to evaluate the safety and tolerability of four doses of SPN-810 in children with ADHD and persistent serious conduct problems.

Timeline

Start: 2008-10-21
Primary completion: 2009-09-23
Completion: 2009-09-23

Publications

Stocks JD, Taneja BK, Baroldi P, Findling RL. A phase 2a randomized, parallel group, dose-ranging study of molindone in children with attention-deficit/hyperactivity disorder and persistent, serious conduct problems. J Child Adolesc Psychopharmacol. 2012 Apr;22(2):102-11. doi: 10.1089/cap.2011.0087. Epub 2012 Feb 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Molindone	Small molecule	1.67 mg	Oral
Subject	Molindone	Small molecule	3.33 mg	Oral
Subject	Molindone	Small molecule	5 mg	Oral
Subject	Molindone	Small molecule	6.67 mg	Oral

Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems

Summary

Timeline

Publications

Drugs

Indications